Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ:INZY) updated its global development strategy for INZ-701, a treatment for ENPP1 ...

ENPP1 Deficiency is a progressively debilitating condition of the vasculature, soft tissue, and skeleton with a prevalence of approximately 1 in 64,000 pregnancies worldwide. Although ENPP1 Deficiency ...

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for ...

Inozyme Pharma, lead candidate INZ-701, is currently in clinical development for ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis. The company expects to reach an agreement on a pivotal study in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization ...

- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients - - ENERGY-3 pivotal trial in ...

BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for ...

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (INZY) (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of ...

A BioMarin Pharmaceutical study of its BMN 401 treatment for children with ENPP1 deficiency met one of its two primary endpoints. ENPP1 deficiency causes a decrease in plasma inorganic pyrophosphate ...

- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global ...